bioAffinity Soars 25.69% on Medicare Coverage Expansion

On April 2, 2025, bioAffinity's stock price surged by 25.69 points in pre-market trading, reflecting a significant upward trend.

bioAffinity recently reported a remarkable 270% increase in revenue, driven by the expansion of Medicare coverage for its innovative products. This substantial growth has positioned the company as a leader in its sector, attracting investor attention and boosting market confidence.

The expansion of Medicare coverage has been a pivotal factor in bioAffinity's recent success. This development has not only increased the demand for the company's products but also expanded its customer base, leading to a surge in revenue. The positive market response to this news has further solidified bioAffinity's position as a key player in the industry.